Rohto Pharmaceutical Coltd Stock Net Income
| RPHCFDelisted Stock | USD 14.72 0.00 0.00% |
Fundamental analysis of Rohto Pharmaceutical allows traders to better anticipate movements in Rohto Pharmaceutical's stock price by examining its financial health and performance throughout various phases of its business cycle.
Rohto |
Rohto Pharmaceutical CoLtd Company Net Income Analysis
Rohto Pharmaceutical's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Rohto Pharmaceutical Net Income | 21.02 B |
Most of Rohto Pharmaceutical's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rohto Pharmaceutical CoLtd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Rohto Pharmaceutical CoLtd reported net income of 21.02 B. This is much higher than that of the Consumer Defensive sector and significantly higher than that of the Household & Personal Products industry. The net income for all United States stocks is significantly lower than that of the firm.
Rohto Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rohto Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Rohto Pharmaceutical could also be used in its relative valuation, which is a method of valuing Rohto Pharmaceutical by comparing valuation metrics of similar companies.Rohto Pharmaceutical is currently under evaluation in net income category among its peers.
Rohto Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0696 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 3.27 B | |||
| Shares Outstanding | 228.14 M | |||
| Shares Owned By Insiders | 13.39 % | |||
| Shares Owned By Institutions | 40.41 % | |||
| Price To Earning | 25.85 X | |||
| Price To Book | 2.57 X | |||
| Price To Sales | 0.02 X | |||
| Revenue | 199.65 B | |||
| Gross Profit | 116.49 B | |||
| EBITDA | 35.87 B | |||
| Net Income | 21.02 B | |||
| Cash And Equivalents | 77.26 B | |||
| Cash Per Share | 677.27 X | |||
| Total Debt | 13.35 B | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 2.27 X | |||
| Book Value Per Share | 877.16 X | |||
| Cash Flow From Operations | 27.25 B | |||
| Earnings Per Share | 0.77 X | |||
| Number Of Employees | 6.87 K | |||
| Beta | 0.14 | |||
| Market Capitalization | 4.15 B | |||
| Total Asset | 274.63 B | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 274.63 B | |||
| Last Dividend Paid | 10.5 |
About Rohto Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rohto Pharmaceutical CoLtd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rohto Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rohto Pharmaceutical CoLtd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Rohto Pink Sheet
If you are still planning to invest in Rohto Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rohto Pharmaceutical's history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |